COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
14 hedge funds and large institutions have $106K invested in COSCIENS Biopharma Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
48% more capital invested
Capital invested by funds: $71.4K → $106K (+$34.1K)
27% more funds holding
Funds holding: 11 → 14 (+3)
0.08% more ownership
Funds ownership: 0.14% → 0.22% (+0.08%)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
92% less call options, than puts
Call options by funds: $45K | Put options by funds: $536K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$33.1K |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$6.58K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.19K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$289 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$200 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$521 |
| 2 |
Morgan Stanley
New York
|
-$366 |
| 3 |
JP Morgan Chase
New York
|
-$189 |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$100 |
| 5 |
IGWM
ICA Group Wealth Management
Denver,
Colorado
|
-$3 |
CSCI Hedge Fund Activity: Q3 2023 in Review
14 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q3 2023, worth a combined $106K — up 48% from $71.4K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CSCI positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $33.1K. The largest seller was Wells Fargo, exiting entirely with an estimated $521 sold.
- 14 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q3 2023, up from 11 in Q2 2023.
- Funds reported $106K of COSCIENS Biopharma Inc. Common Stock stock for Q3 2023, up 48% quarter-over-quarter.
- 4 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q3 2023 and 1 closed out, a net change of +3 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q3 2023 was Two Sigma Securities, an estimated $33.1K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q3 2023 was Wells Fargo, an estimated $521 sold.
Based on aggregated 13F filings for Q3 2023.